11/30
12:37 am
dyn
Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release [Yahoo! Finance]
Medium
Report
Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release [Yahoo! Finance]
11/25
07:19 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.
11/14
10:56 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.
11/12
11:30 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $13.00 to $11.00. They now have a "market perform" rating on the stock.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $13.00 to $11.00. They now have a "market perform" rating on the stock.
11/6
02:04 pm
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Medium
Report
Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
11/6
11:12 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/6
11:11 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target raised by analysts at Royal Bank Of Canada from $23.00 to $30.00. They now have an "outperform" rating on the stock.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target raised by analysts at Royal Bank Of Canada from $23.00 to $30.00. They now have an "outperform" rating on the stock.
11/5
05:47 pm
dyn
Dyne Therapeutics GAAP EPS of -$0.76 [Seeking Alpha]
Low
Report
Dyne Therapeutics GAAP EPS of -$0.76 [Seeking Alpha]
11/5
04:10 pm
dyn
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
High
Report
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/3
07:30 am
dyn
Dyne Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Dyne Therapeutics to Present at Upcoming Investor Conferences
10/24
12:21 pm
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/10
08:43 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
10/10
07:19 am
dyn
Dyne Therapeutics (NASDAQ:DYN) was given a new $13.00 price target on by analysts at Oppenheimer Holdings, Inc..
Low
Report
Dyne Therapeutics (NASDAQ:DYN) was given a new $13.00 price target on by analysts at Oppenheimer Holdings, Inc..
10/8
04:45 pm
dyn
Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 [Seeking Alpha]
Low
Report
Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 [Seeking Alpha]
10/8
12:19 pm
dyn
Dyne Therapeutics (NASDAQ:DYN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/6
06:20 pm
dyn
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) [Yahoo! Finance]
High
Report
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) [Yahoo! Finance]
10/6
06:01 pm
dyn
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
High
Report
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
10/4
05:11 pm
dyn
Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data [Yahoo! Finance]
Medium
Report
Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data [Yahoo! Finance]
10/3
06:42 am
dyn
Dyne Therapeutics' Valuation Leaves No Room For Error [Seeking Alpha]
Medium
Report
Dyne Therapeutics' Valuation Leaves No Room For Error [Seeking Alpha]
10/2
05:39 pm
dyn
Dyne Therapeutics Appoints Brian Posner to its Board of Directors [Yahoo! Finance]
Medium
Report
Dyne Therapeutics Appoints Brian Posner to its Board of Directors [Yahoo! Finance]
10/2
04:05 pm
dyn
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
Medium
Report
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
9/29
09:23 am
dyn
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy [Yahoo! Finance]
9/29
08:35 am
dyn
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
Medium
Report
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
9/14
03:55 am
dyn
Exploring Dyne Therapeutics (DYN) Valuation After Recent Share Price Rebound [Yahoo! Finance]
Low
Report
Exploring Dyne Therapeutics (DYN) Valuation After Recent Share Price Rebound [Yahoo! Finance]
9/10
12:37 am
dyn
Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating [Yahoo! Finance]
Low
Report
Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating [Yahoo! Finance]